<DOC>
	<DOCNO>NCT02093221</DOCNO>
	<brief_summary>This multicenter , randomize , partial-blinded , five-arm , placebo-controlled study human plasma-derived alpha1-proteinase inhibitor ( alpha1-PI ) child ( age 6-11 year old ) teens/adults ( age 12-35 year old ) new onset Type 1 Diabetes Mellitus ( T1DM ) . Currently enrol age 12-35 . Once 25 patient randomize data review enrollment open child cohort . The purpose study evaluate safety efficacy four dosing regimen human plasma-derived alpha1-PI T1DM .</brief_summary>
	<brief_title>Study Human Plasma-Derived Alpha1-Proteinase Inhibitor Subjects With New-Onset Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Diagnosis T1DM accord ADA criterion . Current use inject insulin therapy one positive result test follow antibody ( If currently insulin therapy , must positive result least two antibody ) : Antiisletcell antibody ( islet cell antigen 512 , insulinoma associate protein 2 ) , Antiglutamic acid decarboxylase antibody , Antiinsulin antibody ( unless receive insulin therapy &gt; 7 day ) . Body Mass Index ( BMI ) ≤ 28 kg/m2 adult ( ≥ 20 year age ) OR ≤ 90th percentile accordance Centers Disease Control BMI assessment child teen ( 2 19 year old ) . History current diabetic retinopathy , neuropathy , nephropathy . Known thrombophilia history thrombosis . Malignant disease ( include malignant melanoma ; however , form skin cancer allow ) within five year randomization . Active Hepatitis A virus , Hepatitis B virus , Hepatitis C virus , Human Immunodeficiency Virus infection . History anaphylaxis severe systemic response plasmaderived alpha1PI preparation blood product ( ) . Known selective severe Immunoglobulin A deficiency . Elevated liver enzyme ( aspartate transaminase , alanine aminotransferase , alkaline phosphatase ) equal great 2.5 time upper limit normal . Therapy exenatide agent stimulate pancreatic β cell regeneration insulin secretion , antidiabetic agent ( oral parenteral ) insulin within one month prior screen . Use omega3 fatty acid supplement , include fish oil , within seven day prior screen . Current plan therapy inhaled insulin , become available . Chronic use systemic steroid , exception inhale steroid , stable dose equivalent 5 mg/day prednisone ( e.g. , 10 mg every 2 day ) within 4 week prior randomization . It recommend maintain dose throughout study . ( Note : Subjects autoimmune condition ( i.e. , asthma ) necessitate treatment systemic shortterm corticosteroid administer rapid taper eligible per protocol caveat taper complete decrease minimum requirement ( i.e. , 5 mg/day ) least 1 week prior Baseline visit ( randomization occur ) ensure subject stable . For long term steroid usage , please consult Grifols Medical Monitor consider subject study participation . ) Treatment immunosuppressant cytostatic agent within 6 month randomization .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Alpha1-Proteinase Inhibitor</keyword>
	<keyword>Beta Cell</keyword>
	<keyword>Alpha1-Antitrypsin</keyword>
</DOC>